Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Bioxcel Therapeutics Inc (BTAI)
Bioxcel Therapeutics Inc (BTAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,176
  • Shares Outstanding, K 29,270
  • Annual Sales, $ 380 K
  • Annual Income, $ -165,760 K
  • 60-Month Beta 1.00
  • Price/Sales 235.72
  • Price/Cash Flow N/A
  • Price/Book 15.02
Trade BTAI with:

Options Overview Details

View History
  • Implied Volatility 142.87% ( +25.88%)
  • Historical Volatility 160.18%
  • IV Percentile 81%
  • IV Rank 42.11%
  • IV High 236.42% on 06/27/23
  • IV Low 74.84% on 12/22/22
  • Put/Call Vol Ratio 0.26
  • Today's Volume 98
  • Volume Avg (30-Day) 385
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 13,005
  • Open Int (30-Day) 16,185

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -1.29
  • Number of Estimates 5
  • High Estimate -0.70
  • Low Estimate -1.63
  • Prior Year -1.49
  • Growth Rate Est. (year over year) +13.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.87 +1.57%
on 09/22/23
4.31 -32.48%
on 08/23/23
-1.04 (-26.33%)
since 08/22/23
3-Month
2.87 +1.57%
on 09/22/23
19.07 -84.74%
on 06/26/23
-16.08 (-84.68%)
since 06/22/23
52-Week
2.87 +1.57%
on 09/22/23
34.13 -91.47%
on 02/09/23
-9.04 (-75.65%)
since 09/22/22

Most Recent Stories

More News
Important September 5, 2023 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. Investors of Securities Fraud Class Action Lawsuit

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...

BTAI : 2.91 (-3.64%)
BTAI DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages BioXcel Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important September 5 Deadline in Securities Class Action - BTAI

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) between...

BTAI : 2.91 (-3.64%)
BIOXCEL DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel"...

BTAI : 2.91 (-3.64%)
SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioXcel Therapeutics, Inc.(BTAI) Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI) of a class action securities...

BTAI : 2.91 (-3.64%)
BTAI Investors Have Opportunity to Lead BioXcel Therapeutics, Inc. Securities Fraud Lawsuit

/PRNewswire/ -- Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

BTAI : 2.91 (-3.64%)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioXcel Therapeutics, Inc. - BTAI

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (NASDAQ: BTAI). Such...

BTAI : 2.91 (-3.64%)
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 5, 2023 in the Class Action Filed on Behalf of BioXcel Therapeutics, Inc.(BTAI) Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of BioXcel Therapeutics, Inc. (NASDAQ:...

BTAI : 2.91 (-3.64%)
BTAI CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds BioXcel Therapeutics, Inc. (BTAI) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

/PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in...

BTAI : 2.91 (-3.64%)
BIOXCEL INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioXcel To Contact Him Directly To Discuss Their Options

/PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against BioXcel Therapeutics, Inc. ("BioXcel"...

BTAI : 2.91 (-3.64%)
BIOXCEL SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against BioXcel Therapeutics, Inc. - BTAI

/PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 5, 2023 to file lead plaintiff...

BTAI : 2.91 (-3.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

BioXcel Therapeutics Inc. is a clinical stage biopharmaceutical company. It focuses on drug development which utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's product portfolio include BXCL501, a sublingual thin film...

See More

Key Turning Points

3rd Resistance Point 3.17
2nd Resistance Point 3.10
1st Resistance Point 3.01
Last Price 2.91
1st Support Level 2.84
2nd Support Level 2.77
3rd Support Level 2.67

See More

52-Week High 34.13
Fibonacci 61.8% 22.18
Fibonacci 50% 18.50
Fibonacci 38.2% 14.81
Last Price 2.91
52-Week Low 2.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar